Clinic
Baptist Memorial Hospital - Crittenden INC
Baptist Memorial Hospital - Crittenden INC was paid $4.14M by Medicaid between Dec 2018 and Dec 2024, across 157 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 11% of everything it billed.
33Billing provider infoBAPTIST MEMORIAL HOSPITAL - CRITTENDEN INC
WEST MEMPHIS, AR 72301
WEST MEMPHIS, AR 72301
33aNPI1437634524assigned 09/25/2018
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$4.14M
24GClaims335,657
24DCodes billed157
24AFirst – last monthDec 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Arkansas
Rank by total paid#8 of 24
Median peer was paid$566K
This provider vs. median7.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 668 | $0.00 | |
| 2019 | 62,521 | $500K | |
| 2020 | 58,607 | $714K | |
| 2021 | 54,867 | $715K | |
| 2022 | 57,437 | $802K | |
| 2023 | 58,880 | $779K | |
| 2024incomplete | 42,677 | $633K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 11% | 28,764 | 20,731 | $443K |
| 70450 | Computed tomography, head or brain; without contrast material | 9.2% | 5,607 | 4,501 | $381K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.6% | 3,317 | 2,681 | $316K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 6.8% | 8,773 | 7,071 | $283K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.6% | 5,383 | 4,102 | $273K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5.3% | 5,629 | 4,445 | $218K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 4.2% | 1,249 | 984 | $175K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.4% | 18,985 | 7,865 | $142K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.4% | 27,467 | 19,738 | $139K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.6% | 13,744 | 9,301 | $109K |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.3% | 1,081 | 906 | $94K |
| 83880 | 1.9% | 5,122 | 3,800 | $77K |
145 more codes
| 84484 | 1.8% | 14,686 | $76K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 1,922 | $76K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 6,319 | $67K |
| 99283 | Emergency room visit (moderate) | 1.5% | 2,311 | $63K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 10,619 | $62K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 3,568 | $53K |
| 71250 | 1.2% | 755 | $50K | |
| 83735 | 1.1% | 9,743 | $44K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.1% | 5,339 | $44K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 2,860 | $43K |
| 81025 | 1.0% | 7,274 | $43K | |
| 80050 | General health panel | <1% | 1,051 | $40K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 486 | $33K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,535 | $31K |
| 83690 | <1% | 5,624 | $30K | |
| 81003 | <1% | 15,781 | $29K | |
| 83605 | <1% | 4,809 | $29K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,196 | $28K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 214 | $27K |
| 87040 | <1% | 4,736 | $27K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,535 | $27K |
| 99285 | Emergency room visit (most serious) | <1% | 2,605 | $26K |
| 99284 | Emergency room visit (serious) | <1% | 2,123 | $24K |
| 85027 | <1% | 4,450 | $21K | |
| 73560 | <1% | 1,283 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,104 | $19K |
| 80061 | Lipid panel | <1% | 1,340 | $19K |
| 80320 | <1% | 1,695 | $18K | |
| 82803 | <1% | 1,854 | $18K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 545 | $17K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,659 | $17K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 318 | $16K |
| 80329 | <1% | 1,827 | $16K | |
| 70486 | <1% | 156 | $15K | |
| 73630 | <1% | 776 | $14K | |
| 73030 | <1% | 830 | $14K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,735 | $14K |
| 86901 | <1% | 786 | $14K | |
| 85379 | <1% | 2,121 | $13K | |
| 84703 | <1% | 1,772 | $12K | |
| 73610 | <1% | 749 | $12K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 625 | $11K |
| 90715 | <1% | 833 | $10K | |
| 73130 | <1% | 615 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,132 | $10K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 485 | $9K |
| 72100 | <1% | 567 | $9K | |
| 82565 | <1% | 868 | $9K | |
| 84702 | <1% | 1,099 | $8K | |
| 87807 | <1% | 754 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,114 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,382 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,479 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,600 | $7K |
| 85610 | <1% | 2,703 | $6K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 1,262 | $6K |
| 85730 | <1% | 1,920 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,138 | $6K |
| 82375 | <1% | 898 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 186 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,055 | $5K |
| 94644 | <1% | 246 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 104 | $4K |
| 86140 | <1% | 1,057 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 231 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 213 | $4K |
| 82150 | <1% | 717 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 872 | $4K |
| 81001 | <1% | 1,296 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 15 | $3K |
| 82550 | <1% | 664 | $3K | |
| 87210 | <1% | 583 | $3K | |
| 74018 | <1% | 266 | $3K | |
| 74022 | <1% | 130 | $3K | |
| 83050 | <1% | 898 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 194 | $2K |
| 73110 | <1% | 136 | $2K | |
| G0378 | Hospital observation service, per hour | <1% | 201 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,023 | $2K |
| 10060 | <1% | 13 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 62 | $2K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 20 | $2K |
| 82728 | <1% | 254 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,210 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 15 | $1K |
| 86900 | <1% | 538 | $1K | |
| 85007 | <1% | 460 | $1K | |
| 86850 | <1% | 290 | $824.50 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 684 | $819.99 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 64 | $813.79 |
| 83550 | <1% | 198 | $795.40 | |
| 93971 | <1% | 34 | $722.70 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 84 | $700.21 |
| 83540 | <1% | 218 | $654.33 | |
| 84439 | <1% | 55 | $642.32 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 330 | $553.23 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,064 | $507.23 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,949 | $438.78 |
| 85652 | <1% | 199 | $428.39 | |
| 76801 | <1% | 13 | $427.50 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 185 | $380.37 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 787 | $328.42 |
| 82009 | <1% | 134 | $327.44 | |
| 84100 | <1% | 138 | $325.11 | |
| 82248 | <1% | 58 | $303.09 | |
| 73502 | <1% | 16 | $295.38 | |
| A9270 | Non-covered item or service | <1% | 3,059 | $291.55 |
| 96376 | <1% | 214 | $226.08 | |
| 73590 | <1% | 23 | $225.00 | |
| 96367 | <1% | 59 | $216.92 | |
| 73090 | <1% | 12 | $216.89 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 259 | $202.49 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 356 | $190.14 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 278 | $173.41 |
| 84550 | <1% | 66 | $170.46 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,882 | $160.40 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 472 | $135.08 |
| 83615 | <1% | 36 | $134.35 | |
| 36600 | <1% | 1,378 | $112.58 | |
| 82140 | <1% | 15 | $108.29 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 177 | $93.44 |
| 87070 | <1% | 18 | $86.10 | |
| 84145 | <1% | 16 | $86.07 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 100 | $67.60 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,773 | $63.10 |
| 82272 | <1% | 63 | $60.73 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 248 | $52.31 |
| 87205 | <1% | 18 | $42.70 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 452 | $39.65 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 171 | $30.61 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 14 | $21.85 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 70 | $20.51 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 18 | $16.40 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 32 | $7.29 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,815 | $1.14 |
| 99406 | 0% | 133 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 157 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 66 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 63 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 111 | $0.00 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 79 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 44 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 25 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 26 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUCKETT, GREGORY (SR VP/CLO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.